



1609/IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in Re:
U.S. Patent Application

Applicant: Michael J. Pugia, et al.
Serial No. 10/574,862

Filed: April 6, 2006

For: **Monoclonal Antibodies for Detection of
Urinary Trypsin Inhibitors**

) Customer No. 47670
)
) Attorney Docket: 017191.0049
)
)
)
)
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Statement Under 37 C.F.R. 1.804(b)

A copy of a deposit receipt from ATCC is enclosed. The three murine hybridoma cell lines identified in the receipt are those identified in the subject patent application, as corroborated by the enclosed statement by the first-named inventor.

Respectfully submitted,

3/8/07
Date

Harold Wells
Reg. No. 26,044
Kelley Drye & Warren LLP
333 West Wacker Drive, Suite 2600
Chicago, IL 60606
(312) 857-7070
(312) 857-7095 (Fax)

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO RULE 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 10.2

To: (Name and Address of Depositor or Attorney)

Bayer Healthcare LLC
ATTN: David Brock1884 Miles Ave.
Elkhart, IN 46514

Deposited on Behalf of: Bayer Healthcare LLC

Identification Reference by Depositor:

Murine Hybridoma Cell Line: 420-5D11.5G8-1E4
Murine Hybridoma Cell Line: 421-5G8.1A8.5C1
Murine Hybridoma Cell Line: 421-3G5.4C5.3B6

Patent Deposit Designation

PTA-7744
PTA-7745
PTA-7746The deposit was accompanied by: a scientific description a proposed taxonomic description indicated above.

The deposit was received, July 28,2006 by this International Depository Authority and has been accepted.

AT YOUR REQUEST: We will inform you of requests for the strain for 30 years.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strain.


If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested, August 14,2006. On that date, the culture was viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:



Dee Bishop, ATCC Patent Depository

Date: August 16, 2006

cc: Bayer Healthcare LLC Kevin Stein



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: (REDACTED)

) Customer No. 47670

U.S. Patent Application

) Attorney Docket: 017191.0049

Applicant: Michael J. Pugia, et al.

Serial No. 10/574,862

Filed: April 6, 2006

For: **Monoclonal Antibodies for Detection of**

Urinary Trypsin Inhibitors

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


Sir:

Statement Under 37 C.F.R. 1.804(b)

The three murine hybridoma cell lines designated as PTA-7744, 7745 and 7746 in the accompanying ATCC deposit receipt were deposited by David Brock at my direction. These three cell lines are those identified in the subject application by the reference numbers provided by the Depositor.

Mar 1 07
Date

Respectfully submitted,


Michael J. Pugia, Ph.D.